An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
Dichlororibofuranosylbenzimidazole has been studied across 8 research domains including 🔬 Oncology, 🧬 Hormones, 🏋️ Muscle & Hypertrophy, ⚡ Energy & Fatigue, 😴 Sleep. The primary research focus is 🔬 Oncology with 27% of studies addressing this area.
The following compounds share molecular targets with Dichlororibofuranosylbenzimidazole, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Dichlororibofuranosylbenzimidazole is generated deterministically from 26 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.